This week on LATAM MedTech Insights, we dissect the groundbreaking new Software as a Medical Device (SaMD) regulation just released by Brazil's ANVISA. This isn't just another update; it's a complete strategic reset for any digital health company targeting the Brazilian market. We explore the critical changes in risk classification for AI-driven software and the stringent new cybersecurity mandates that have just come into effect.

Imagine a cutting-edge European AI diagnostics startup, poised to enter Brazil as its gateway to Latin America. Last week, their entire market access strategy was invalidated by ANVISA's new resolution. Their product's classification has jumped from low-risk to high-risk, demanding extensive clinical data they haven't prepared for. This episode details the pivots and strategies companies in this exact situation must now consider.

Key Takeaways:

1. What specific event triggered ANVISA's major overhaul of its SaMD regulations?

2. How do the new AI risk classifications diverge from established FDA or EU guidelines?

3. What are the most overlooked cybersecurity requirements in the new Brazilian framework?

4. For SaMDs now classified as high-risk, what are the specific clinical evidence demands?

5. How will this regulatory shift impact foreign investment in Brazil's digital health sector?

6. Are there any provisions for legacy software already on the market?

7. What new documentation for data privacy is now mandatory for submission?

Navigating this new landscape is complex, but Pure Global is built for this challenge. We offer end-to-end regulatory consulting, using our local Brazilian expertise and advanced AI tools to streamline your path to market. From developing a new regulatory strategy to compiling your technical dossier for ANVISA, we ensure your innovation meets these new standards efficiently. Don't let regulatory shifts derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market access.